{"id":32664,"date":"2024-07-03T12:28:40","date_gmt":"2024-07-03T12:28:40","guid":{"rendered":"https:\/\/ibima.eu\/estudio-de-fase-iii-sin-enmascaramiento-de-un-unico-grupo-multicentrico-para-evaluar-la-farmacocinetica-la-farmacodinamica-la-eficacia-la-seguridad-y-la-inmunogenicidad-del-ravulizumab-administr\/"},"modified":"2024-07-03T12:28:40","modified_gmt":"2024-07-03T12:28:40","slug":"estudio-de-fase-iii-sin-enmascaramiento-de-un-unico-grupo-multicentrico-para-evaluar-la-farmacocinetica-la-farmacodinamica-la-eficacia-la-seguridad-y-la-inmunogenicidad-del-ravulizumab-administr","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-de-fase-iii-sin-enmascaramiento-de-un-unico-grupo-multicentrico-para-evaluar-la-farmacocinetica-la-farmacodinamica-la-eficacia-la-seguridad-y-la-inmunogenicidad-del-ravulizumab-administr\/","title":{"rendered":"Estudio de fase III, sin enmascaramiento, de un \u00fanico grupo, multic\u00e9ntrico para evaluar la farmacocin\u00e9tica, la farmacodin\u00e1mica, la eficacia, la seguridad y la inmunogenicidad del ravulizumab administrado por v\u00eda intravenosa en participantes pedi\u00e1tricos (de 6 a <18 (MGg)"},"content":{"rendered":"
VIRGINIA REYES GARRIDO – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – ALEXION PHARMACEUTICALS, INC<\/p>","protected":false},"excerpt":{"rendered":"
VIRGINIA REYES GARRIDO – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – ALEXION PHARMACEUTICALS, INC<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2283],"tags":[],"class_list":["post-32664","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-c-01-ensayos-clinicos"],"acf":[],"yoast_head":"\n